J. Hoffmann

发表

Molecular Mode of Action and Role of TP53 in the Sensitivity to the Novel Epothilone Sagopilone (ZK-EPO) in A549 Non-Small Cell Lung Cancer Cells

S. Winsel, A. Sommer, J. Eschenbrenner, 2011, PloS one.

Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.

N. Blüthgen, I. Fichtner, B. Klinger, 2020, Advances in biological regulation.

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Martin R. Schneider, N. Heinrich, J. Hoffmann, 2004, Journal of the National Cancer Institute.

Mutation Status of KRAS, BRAF, PIK3CA and Expression Level of AREG and EREG Identify Responders to Cetuximab in a Large Panel of Patient Derived Colorectal Carcinoma Xenografts of All Four UICC Stages

A. Rosenthal, I. Klaman, I. Fichtner, 2013 .

Predictive In Vivo Models for Oncology.

J. Hoffmann, J. Rolff, D. Behrens, 2016, Handbook of experimental pharmacology.

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

I. Tinhofer, J. Hoffmann, J. Raguse, 2020, Oncotarget.

A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies

J. Hoffmann, M. Schwab, B. Jandrig, 2022, Frontiers in Oncology.

Sagopilone Inhibits Breast Cancer Bone Metastasis and Bone Destruction Due to Simultaneous Inhibition of Both Tumor Growth and Bone Resorption

U. Klar, J. Hoffmann, S. Käkönen, 2009, Clinical Cancer Research.

Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN‐amplified neuroblastoma

J. Wolf, J. Hoffmann, J. Schulte, 2020, International journal of cancer.

Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6

H. Lehrach, C. Regenbrecht, J. Hoffmann, 2017, Oncotarget.

Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis.

J. Hoffmann, W. Walther, M. Becker, 2021, Methods in molecular biology.

Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.

I. Fichtner, J. Hoffmann, M. Becker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen Bicalutamide (Casodex) in a New Prostate Cancer Model

H. Klocker, G. Bartsch, J. Hoffmann, 2000, Urologia Internationalis.

Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker

J. Hoffmann, W. Walther, S. Burock, 2022, British Journal of Cancer.

IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer

Robert Reihs, Y. N. Park, J. Hoffmann, 2017, Oncotarget.

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

H. Klocker, G. Bartsch, D. Zopf, 2002, Cancer Gene Therapy.

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate

U. Klar, J. Hoffmann, M. Giurescu, 2008, Expert opinion on investigational drugs.

Subcellular distribution of epothilones in human tumor cells

U. Klar, J. Hoffmann, T. Bunte, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Investigational developments for the treatment of progesterone-dependent diseases

J. Hoffmann, T. Kirkland, Thomas A. Kirkland, 2008 .

Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models

P. Mertins, C. Regenbrecht, J. Hoffmann, 2021, Molecular Cancer.

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.

U. Klar, J. Hoffmann, M. Giurescu, 2008, Expert opinion on investigational drugs.

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

Martin R. Schneider, H. Klocker, G. Bartsch, 1999, British Journal of Cancer.

Aranciamycin analogs generated by combinatorial biosynthesis show improved antitumor activity

J. Hoffmann, A. Bechthold, A. Vente, 2008, Applied Microbiology and Biotechnology.

Sagopilone(ZK-EPO):froma naturalproducttoafullysynthetic clinicaldevelopmentcandidate

U. Klar, J. Hoffmann, M. Giurescu, 2008 .

Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development.

Wolfgang Schwede, Ulrich Klar, Werner Skuballa, 2006, Angewandte Chemie.

Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.

J. Hoffmann, A. Menrad, M. Schirner, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

Catherine L. Worth, T. Borodina, H. Lehrach, 2017, Nature Communications.

Anti‐tumor efficacy of the nucleoside analog 1‐(2‐deoxy‐2‐fluoro‐4‐thio‐β‐D‐arabinofuranosyl) cytosine (4′‐thio‐FAC) in human pancreatic and ovarian tumor xenograft models

J. Hoffmann, E. Ho, H. Dinter, 2005, International journal of cancer.

Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.

A. Sommer, J. Hoffmann, 2005, The Journal of steroid biochemistry and molecular biology.

A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option

I. Fichtner, J. Hoffmann, T. Plath, 2015, International journal of cancer.

Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures

M. Boerries, Dirk Schumacher, R. Schäfer, 2019, PLoS genetics.

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

A. Rosenthal, Robert Schmieder, D. Zopf, 2014, International journal of cancer.

Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers

Michael Becker, Iduna Fichtner, Richie Soong, 2008, Clinical Cancer Research.

Rapid testing of candidate oncogenes and tumour suppressor genes in signal transduction and neoplastic transformation.

R. Schäfer, J. Hoffmann, C. Sers, 2021, Advances in biological regulation.

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

Z. Szallasi, P. Futreal, A. Eklund, 2010, Genome Medicine.

Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.

J. Hoffmann, K. Chwalisz, U. Fuhrmann, 2000, Journal of medicinal chemistry.

Choosing wisely - Preclinical test models in the era of precision medicine.

J. Hoffmann, W. Walther, K. Klinghammer, 2017, Cancer treatment reviews.

In Vitro Three-Dimensional Cell Cultures as Tool for Precision Medicine

Dirk Schumacher, R. Schäfer, C. Regenbrecht, 2017 .

Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer

I. Fichtner, A. Sommer, U. Klar, 2010, Clinical Cancer Research.

Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.

H. Popper, M. Asslaber, C. Regenbrecht, 2018, European journal of cancer.

Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data

M. Yaspo, H. Lehrach, J. Hoffmann, 2021, Cancers.

Basal subtype is predictive for response to cetuximab treatment in patient‐derived xenografts of squamous cell head and neck cancer

U. Leser, I. Tinhofer, I. Fichtner, 2017, International journal of cancer.

Evaluation of Activity and Combination Strategies with the Microtubule-Targeting Drug Sagopilone in Breast Cancer Cell Lines

S. Winsel, A. Sommer, J. Eschenbrenner, 2011, Front. Oncol..

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine

I. Fichtner, J. Hoffmann, C. Sers, 2020, Neoplasia.

Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain

W. Birchmeier, E. Gherardi, J. Hoffmann, 2017, Scientific Reports.

Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts

I. Fichtner, J. Hoffmann, J. Rolff, 2016, Targeted Oncology.

Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts

J. Hoffmann, S. Sebens, M. Becker, 2022, Communications Biology.

Breaking the Crosstalk of the Cellular Tumorigenic Network in NSCLC by a Highly Effective Drug Combination

J. Hoffmann, S. Sebens, C. Röcken, 2021 .

Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts

J. Hoffmann, S. Sebens, C. Röcken, 2022, Communications Biology.

RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance

J. Testa, J. Hoffmann, D. Wiest, 2019, PloS one.

Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.

I. Fichtner, J. Hoffmann, M. Hentschel, 1994, Anticancer research.

In vitro characterization of ZK 230211—A type III progesterone receptor antagonist with enhanced antiproliferative properties

J. Hoffmann, C. Otto, U. Fuhrmann, 2010, The Journal of Steroid Biochemistry and Molecular Biology.

Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer

A. Sommer, J. Hoffmann, 2006 .

Steroidhormone receptors as targets for the therapy of breast and prostate cancer—recent advances, mechanisms of resistance, and new approaches

A. Sommer, J. Hoffmann, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Studies on the development of resistance to the pure antiestrogen Faslodex™ in three human breast cancer cell lines

Martin R. Schneider, A. Sommer, J. Hoffmann, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.

P. Lienau, I. Fichtner, U. Klar, 2009, Neuro-oncology.

Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas

I. Fichtner, J. Hoffmann, P. Vajkoczy, 2018, Journal of Cancer Research and Clinical Oncology.

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.

L. Galluzzi, J. Vicencio, G. Kroemer, 2008, Cancer research.

Progesterone receptor antagonists (antiprogestins)

J. Hoffmann, U. Fuhrmann, H. Hess-Stumpp, 2002 .

A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells.

Martin R. Schneider, J. Hoffmann, A. Menrad, 1997, Cancer research.

A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers

M. Hayman, J. Hoffmann, K. Klinghammer, 2018, International journal of cancer.

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

A. Jödicke, I. Fichtner, J. Hoffmann, 2023, Frontiers in Oncology.

Integrative oncology drug discovery accompanied by preclinical translational research as prerequisite for clinical development.

J. Hoffmann, 2014, Chinese clinical oncology.

New synthetic Epothilone Derivative ZK-EPO inhibits breast cancer metastasis

U. Klar, J. Hoffmann, H. Pietsch, 2005 .

Preclinical and clinical development of new progesterone receptor antagonists with high receptor specificity for breast cancer treatment

J. Hoffmann, G. Siemeister, U. Fuhrmann, 2020 .

Effects of progesterone receptor antagonists on breast cancer

Martin R. Schneider, J. Hoffmann, K. Chwalisz, 2002 .

Animal models for personalized treatment options.

I. Fichtner, J. Hoffmann, B. Jandrig, 2017, International journal of clinical pharmacology and therapeutics.

A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer

Marcel H. Schulz, M. Yaspo, H. Lehrach, 2023, Molecular Cancer.

5009 ORAL Significant antitumour activity of the novel epothilone ZK-EPO against in vitro and in vivo models of ovarian cancer

S. Winsel, A. Sommer, U. Klar, 2007 .

Integrative oncology drug discovery accompanied by preclinical translational research as prerequisite for clinical development.

J. Hoffmann, 2014, Chinese clinical oncology.

Employing head and neck cancer patient derived xenografts to inform clinical trial design: Results from combining regorafenib with everolimus.

I. Fichtner, D. Zopf, J. Hoffmann, 2015 .